微信直播

首届中国肺癌精准诊疗论坛|Billy Loo: 肿瘤放射治疗之经验

Published at: 2015年第1卷第S1期

钟清华
关键词:

编者按:2016年5月6–7日,由赫捷院士和孙燕院士担任大会主席,王绿化教授、高树庚教授和王洁教授担任执行主席的第一届中国肺癌精准诊疗论坛在北京成功举办。作为大会讲者,来自斯坦福大学医学中心放疗科的 Dr. Billy Loo 医生接受 AME 专访,围绕肺癌 TOMO 治疗时正常肺组织的剂量问题、肺癌大分割放疗远隔效应中可以联合应用的免疫治疗问题、质子治疗在局部晚期鼻咽癌在危及器官的剂量问题做了回答,并描述了他的医患关系状况。

 

最后,感谢泉州市第一医院肿瘤放疗科主治医师蔡文杰医生对采访问题的设计

采访问题

  1. What is your suggested dosage limits for normal tissue in TOMO for lung cancer? 

  2. What do you think is the most applicable immunotherapy to combine remote effect of hypo-fractionated radiation therapy for lung cancer?

  3. For locally advanced nasopharyngeal carcinoma implicating organs at risk, proton beam therapy is a better option than X-ray therapy. How do you define the dosage limits for organ at risk, for instance, brainstem?

  4. May I ask how close between you and your patients in your clinical practice? What is the most appropriate distance or relationship between doctors and patients? 

访谈视频


受访专家

Dr. Billy W. Loo,

Associate Professor of Radiation Oncology, 

Stanford University Medical Center

采访编辑丨钟清华,科学编辑,AME 出版社;

视频编辑丨麦雪芳,视频编辑,AME 出版社。

doi:10.3978/kysj.2014.1.1876

comments powered by Disqus

附件